Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:INBXNASDAQ:INMBNASDAQ:NBRVNASDAQ:PRQR On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeINBXInhibrx$12.86+2.6%$12.50$10.80▼$34.58$186.16MN/A159,592 shs73,671 shsINMBINmune Bio$7.30-2.7%$7.61$4.32▼$10.50$167.78M1.63261,560 shs304,816 shsNBRVNabriva Therapeutics$0.00$1.22▼$8.45$45.46M1.5329,344 shs472 shsPRQRProQR Therapeutics$1.67-1.2%$1.46$1.07▼$4.62$175.71M0.35629,590 shs298,231 shs13 Stocks Institutional Investors Won't Stop BuyingWhich stocks are hedge funds and endowments buying in today's market? Enter your email address and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying now.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceINBXInhibrx+2.55%+4.30%+5.76%+2.39%-62.63%INMBINmune Bio-2.67%-7.12%-11.41%-15.02%-31.78%NBRVNabriva Therapeutics0.00%0.00%0.00%+4,900.00%+4,900.00%PRQRProQR Therapeutics-1.18%+3.09%+14.38%-34.77%-13.92%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationINBXInhibrx2.2642 of 5 stars0.02.00.04.62.92.51.3INMBINmune Bio1.3613 of 5 stars3.61.00.00.00.01.70.6NBRVNabriva TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/APRQRProQR Therapeutics3.2791 of 5 stars4.65.00.00.03.30.00.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceINBXInhibrx 2.00HoldN/AN/AINMBINmune Bio 3.17Buy$22.80212.33% UpsideNBRVNabriva Therapeutics 0.00N/AN/AN/APRQRProQR Therapeutics 3.13Buy$8.00379.04% UpsideCurrent Analyst Ratings BreakdownLatest NBRV, INBX, PRQR, and INMB Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/15/2025INBXInhibrxJMP SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingMarket Perform ➝ Market Perform5/13/2025PRQRProQR TherapeuticsOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOutperform ➝ Outperform$15.00 ➝ $9.004/29/2025PRQRProQR TherapeuticsCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOverweight$8.004/29/2025PRQRProQR TherapeuticsEvercore ISISubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOutperform$5.003/14/2025PRQRProQR TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$10.00 ➝ $12.003/14/2025PRQRProQR TherapeuticsChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$4.00 ➝ $4.003/10/2025PRQRProQR TherapeuticsCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeNeutral ➝ Buy$4.00(Data available from 5/24/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookINBXInhibrx$200K930.81N/AN/AN/A∞INMBINmune Bio$50K3,355.66N/AN/A$2.07 per share3.53NBRVNabriva Therapeutics$35.59M0.00N/AN/A$0.10 per share0.00PRQRProQR Therapeutics$18.97M9.26N/AN/A$0.55 per share3.04Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateINBXInhibrx-$154.96M$116.750.11N/AN/AN/A-113.74%-80.56%6/16/2025 (Estimated)INMBINmune Bio-$30.01M-$1.93N/AN/AN/AN/A-117.48%-78.96%8/7/2025 (Estimated)NBRVNabriva Therapeutics-$57.19M-$19.20N/AN/AN/A-148.11%-365.53%-135.81%N/APRQRProQR Therapeutics-$30.43M-$0.35N/AN/AN/A-134.31%-71.58%-19.70%N/ALatest NBRV, INBX, PRQR, and INMB EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/14/2025Q4 2024INBXInhibrx-$2.55-$2.80-$0.25-$2.80N/AN/A5/8/2025Q1 2025INMBINmune Bio-$0.43-$0.43N/A-$0.43N/A$0.05 million5/8/2025Q1 2025PRQRProQR Therapeutics-$0.09-$0.1082-$0.0182-$0.11$4.90 million$4.89 million3/27/2025Q4 2024INMBINmune Bio-$0.54-$0.40+$0.14-$0.40N/AN/A3/17/2025Q4 2024INBXInhibrx-$2.88-$3.09-$0.21-$3.09N/A$0.10 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthINBXInhibrxN/AN/AN/AN/AN/AINMBINmune BioN/AN/AN/AN/AN/ANBRVNabriva TherapeuticsN/AN/AN/AN/AN/APRQRProQR TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioINBXInhibrxN/A4.704.70INMBINmune BioN/A2.592.59NBRVNabriva Therapeutics0.120.850.52PRQRProQR TherapeuticsN/A2.332.33Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipINBXInhibrx82.46%INMBINmune Bio12.72%NBRVNabriva Therapeutics0.27%PRQRProQR Therapeutics32.65%Insider OwnershipCompanyInsider OwnershipINBXInhibrx17.09%INMBINmune Bio35.20%NBRVNabriva Therapeutics1.63%PRQRProQR Therapeutics8.40%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableINBXInhibrx16614.48 million11.26 millionOptionableINMBINmune Bio1022.98 million14.37 millionOptionableNBRVNabriva Therapeutics7032.02 million31.49 millionNot OptionablePRQRProQR Therapeutics180105.21 million74.82 millionOptionableNBRV, INBX, PRQR, and INMB HeadlinesRecent News About These CompaniesPoint72 Asset Management L.P. Takes Position in ProQR Therapeutics (NASDAQ:PRQR)May 22 at 4:42 AM | marketbeat.comFY2025 EPS Forecast for ProQR Therapeutics Cut by AnalystMay 16, 2025 | marketbeat.comOCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC Invests $602,000 in ProQR Therapeutics (NASDAQ:PRQR)May 16, 2025 | marketbeat.comOppenheimer Cuts ProQR Therapeutics (NASDAQ:PRQR) Price Target to $9.00May 16, 2025 | americanbankingnews.comProQR Therapeutics (PRQR) Price Target Lowered by Oppenheimer | PRQR Stock NewsMay 13, 2025 | gurufocus.comProQR Announces Upcoming Scientific Presentations at ASGCT and TIDES ConferencesMay 12, 2025 | globenewswire.comProQR Therapeutics (NASDAQ:PRQR) Receives Average Recommendation of "Buy" from AnalystsMay 12, 2025 | marketbeat.comProQR Therapeutics Advances Axiomer RNA Editing Pipeline with Leadership Appointments and Strong Financial PositionMay 10, 2025 | nasdaq.comProQR Therapeutics (NASDAQ:PRQR) Shares Acquired by DAFNA Capital Management LLCMay 10, 2025 | marketbeat.comProQR Therapeutics N.V.: ProQR Announces First Quarter 2025 Operating and Financial ResultsMay 10, 2025 | finanznachrichten.deProQR Therapeutics N.V.: ProQR Announces First Quarter 2025 Operating and Financial ResultsMay 10, 2025 | finanznachrichten.deNew Forecasts: Here's What Analysts Think The Future Holds For ProQR Therapeutics N.V. (NASDAQ:PRQR)May 10, 2025 | finance.yahoo.comProQR: Q1 Earnings SnapshotMay 10, 2025 | finance.yahoo.comProQR: Q1 Earnings SnapshotMay 10, 2025 | finance.yahoo.comProQR Announces First Quarter 2025 Operating and Financial ResultsMay 8, 2025 | globenewswire.com1,181,413 Shares in ProQR Therapeutics (NASDAQ:PRQR) Acquired by ArrowMark Colorado Holdings LLCMay 6, 2025 | marketbeat.comEquities Analysts Set Expectations for PRQR FY2025 EarningsMay 3, 2025 | marketbeat.comProQR Therapeutics (PRQR) Expected to Announce Quarterly Earnings on ThursdayMay 3, 2025 | marketbeat.comProQR Announces Webcast of Presentation at the 2025 Citizens Life Sciences ConferenceMay 2, 2025 | globenewswire.comProQR Therapeutics (NASDAQ:PRQR) Shares Acquired by Boothbay Fund Management LLCMay 2, 2025 | marketbeat.comProQR Therapeutics (NASDAQ:PRQR) Now Covered by Cantor FitzgeraldMay 1, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeNBRV, INBX, PRQR, and INMB Company DescriptionsInhibrx NASDAQ:INBX$12.86 +0.32 (+2.55%) Closing price 05/23/2025 04:00 PM EasternExtended Trading$12.88 +0.02 (+0.12%) As of 05/23/2025 06:07 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Inhibrx, Inc., a clinical-stage biopharmaceutical company, develops a pipeline of novel biologic therapeutic candidates. The company's therapeutic candidate includes INBRX-101, an alpha-1 antitrypsin (AAT)-Fc fusion protein therapeutic candidate, which is in Phase 1 clinical trials for use in the treatment of patients with AAT deficiency. It also develops INBRX-109, a tetravalent therapeutic candidate targeting death receptor 5, which is in Phase 2 clinical trials to treat cancers, such as chondrosarcoma, mesothelioma, colorectal cancer, ewing sarcoma, and pancreatic adenocarcinoma; and INBRX-106, a hexavalent agonist of OX40 for a range of oncology indications. The company has license and collaboration agreements with 2seventy bio, Inc. and Bristol-Myers Squibb Company. Inhibrx, Inc. was incorporated in 2009 and is headquartered in La Jolla, California.INmune Bio NASDAQ:INMB$7.30 -0.20 (-2.67%) Closing price 05/23/2025 04:00 PM EasternExtended Trading$7.28 -0.01 (-0.21%) As of 05/23/2025 07:32 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.INmune Bio, Inc., a clinical-stage immunology company, focuses on developing drugs to reprogram the patients innate immune system to treat disease in the United States. It intends to develop and commercialize product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation. The company's development programs include INKmune, which is in Phase 1 for the treatment of patients with high-risk myelodysplastic syndrome; and INB03, a mucinous polyglucan on the surface of some epithelial cancer cells that appears to predict resistant to immunotherapy, including women with MUC4 expressing HER2+ breast cancer and other MUC4 resistant cancers. It also provides XPro1595 for the treatment of Alzheimer's disease and treatment resistant depression. It has license agreements with Xencor, Inc.; Immune Ventures, LLC; and University of Pittsburg. INmune Bio, Inc. was incorporated in 2015 and is headquartered in Boca Raton, Florida.Nabriva Therapeutics NASDAQ:NBRVNabriva Therapeutics plc, a biopharmaceutical company, engages in the development and commercialization of novel anti-infective agents to treat serious infections. The company's product includes SIVEXTRO, an oxazolidinone-class antibacterial for the treatment of acute bacterial skin and skin structure infection (ABSSSI); and XENLETA, a semi-synthetic pleuromutilin antibiotic for oral and IV administration. It also develops XENLETA that is in Phase I clinical trial for the treatment of pediatric infections, as well as sexually transmitted infections, cystic fibrosis, ABSSSI, ventilator-associated bacterial pneumonia, complicated intra-abdominal infections, hospital-acquired bacterial pneumonia, acute bacterial skin and skin structure infections, osteomyelitis, and prosthetic joint infections. In addition, the company develops CONTEPO, an epoxide antibiotic for use in treating complicated urinary tract infections, as well as is in Phase I clinical trial for peri-operative prophylaxis. The company was formerly known as Nabriva Therapeutics Forschungs GmbH and changed its name to Nabriva Therapeutics plc in 2007. Nabriva Therapeutics plc was incorporated in 2005 and is headquartered in Dublin, Ireland.ProQR Therapeutics NASDAQ:PRQR$1.67 -0.02 (-1.18%) Closing price 05/23/2025 04:00 PM EasternExtended Trading$1.68 +0.02 (+0.90%) As of 05/23/2025 05:42 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.ProQR Therapeutics N.V., a biotechnology company, focuses on the discovery and development of novel therapeutic medicines. The company's products pipeline includes AX-0810 for cholestatic diseases targeting Na-taurocholate cotransporting polypeptide (NTCP); and AX-1412 for cardiovascular diseases (CVDs) targeting Beta-1,4-galactosyltransferase 1 (B4GALT1). It also develops various other early-stage research programs, including AX-1005 for undisclosed targets in CVDs; AX-2402, which focuses on Rett syndrome; AX-2911 for nonalcoholic steatohepatitis (NASH); AX-0601 for obesity and Type 2 diabetes; and AX-9115 for rare metabolic condition, as well as various other targets. In addition, the company develops Axiomer RNA base-editing platform technology. It has a license agreement with Radboud University Medical Center; Inserm Transfert SA; Ionis Pharmaceuticals, Inc.; Vico Therapeutics B.V.; University of Rochester; and Leiden University Medical Center, as well as license and research collaboration with Eli Lilly and Company for the discovery, development, and commercialization of potential new medicines for genetic disorders in the liver and nervous system. The company was incorporated in 2012 and is headquartered in Leiden, the Netherlands. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Turbulence for Joby Shares: What's Behind the Recent Dip? Pfizer's 7.5% Dividend: Income Haven or House of Cards? TJX Stock Price Stumble Is Your Chance to Pick Up a Bargain Advance Auto Parts Jumps on Surprise Earnings Beat Costco Stock at $1K: Dominance or Danger Zone? Williams-Sonoma: A Fundamentally Good Buy On Sale Now Snowflake Breaks Out! Can It Drift Higher in 2025 and Beyond? Alphabet Gets JPMorgan’s Vote of Confidence After Google I/O Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
